Literature DB >> 23406672

Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial.

Mads J Andersen1, Mads Ersbøll, Anna Axelsson, Finn Gustafsson, Christian Hassager, Lars Køber, Barry A Borlaug, Søren Boesgaard, Lene T Skovgaard, Jacob E Møller.   

Abstract

BACKGROUND: Diastolic dysfunction is frequently seen after myocardial infarction and is characterized by a disproportionate increase in filling pressure during exercise to maintain stroke volume. We hypothesized that sildenafil would reduce filling pressure during exercise in patients with diastolic dysfunction after myocardial infarction. METHODS AND
RESULTS: Seventy patients with diastolic dysfunction and near normal left ventricular ejection fraction on echocardiography were randomly assigned sildenafil 40 mg thrice daily or matching placebo for 9 weeks. Before randomization and after 9 weeks of treatment patients underwent simultaneous echocardiography and right heart catheterization at rest and during exercise. Primary end point was pulmonary capillary wedge pressure, and secondary end points comprised cardiac index and pulmonary arterial pressure at rest and during exercise after 9 weeks. After 9 weeks there were no differences in pulmonary capillary wedge pressure at rest (13±4 versus 13±3 mm Hg, P=0.25) or at peak exercise (35±8 mm Hg versus 31±7 mm Hg, P=0.07). However, with treatment cardiac index increased at rest (P=0.006) and peak exercise (P=0.02) in the sildenafil group, and systemic vascular resistance index (resting, P=0.0002; peak exercise, P=0.007) and diastolic blood pressure (resting, P=0.005; peak exercise, P=0.02) were lower in the sildenafil group. Resting left ventricular end-diastolic volume index increased (P=0.001) within the sildenafil group but was unchanged in the placebo group.
CONCLUSIONS: Sildenafil did not decrease filling pressure at rest or during exercise in post-myocardial infarction patients with diastolic dysfunction. However, there were effects on secondary end points, which require further studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23406672     DOI: 10.1161/CIRCULATIONAHA.112.000056

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  30 in total

Review 1.  Nitric oxide signalling in cardiovascular health and disease.

Authors:  Charlotte Farah; Lauriane Y M Michel; Jean-Luc Balligand
Journal:  Nat Rev Cardiol       Date:  2018-02-01       Impact factor: 32.419

Review 2.  Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?

Authors:  R Pofi; D Gianfrilli; R Badagliacca; C Di Dato; M A Venneri; E Giannetta
Journal:  J Endocrinol Invest       Date:  2015-07-05       Impact factor: 4.256

Review 3.  cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.

Authors:  Linda S Hoffmann; Horng H Chen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-06-15       Impact factor: 3.000

4.  Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis.

Authors:  Enrico Patrucco; Katrin Domes; Mauro Sbroggió; Anne Blaich; Jens Schlossmann; Matthias Desch; Sergei D Rybalkin; Joseph A Beavo; Robert Lukowski; Franz Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-19       Impact factor: 11.205

Review 5.  PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.

Authors:  Anindita Das; David Durrant; Fadi N Salloum; Lei Xi; Rakesh C Kukreja
Journal:  Pharmacol Ther       Date:  2014-10-31       Impact factor: 12.310

6.  Sildenafil ameliorates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure model.

Authors:  Chun-kai Huang; Bi-yi Chen; Ang Guo; Rong Chen; Yan-qi Zhu; William Kutschke; Jiang Hong; Long-sheng Song
Journal:  Acta Pharmacol Sin       Date:  2016-03-14       Impact factor: 6.150

Review 7.  Medication management of chronic heart failure in older adults.

Authors:  Kannayiram Alagiakrishnan; Maciej Banach; Linda G Jones; Ali Ahmed; Wilbert S Aronow
Journal:  Drugs Aging       Date:  2013-10       Impact factor: 3.923

Review 8.  Heart failure with preserved ejection fraction.

Authors:  James D Gladden; Wolfgang A Linke; Margaret M Redfield
Journal:  Pflugers Arch       Date:  2014-03-25       Impact factor: 3.657

Review 9.  Pulmonary Hypertension in Patients With Heart Failure With Mid-Range Ejection Fraction.

Authors:  Micha T Maeder; Lukas Weber; Marc Buser; Roman Brenner; Lucas Joerg; Hans Rickli
Journal:  Front Cardiovasc Med       Date:  2021-07-09

10.  Osteocrin, a novel myokine, prevents diabetic cardiomyopathy via restoring proteasomal activity.

Authors:  Xin Zhang; Can Hu; Xiao-Pin Yuan; Yu-Pei Yuan; Peng Song; Chun-Yan Kong; Teng Teng; Min Hu; Si-Chi Xu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Cell Death Dis       Date:  2021-06-16       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.